• Aucun résultat trouvé

The MeLiM pig : a model for cutaneous melanoma

N/A
N/A
Protected

Academic year: 2021

Partager "The MeLiM pig : a model for cutaneous melanoma"

Copied!
2
0
0

Texte intégral

(1)

HAL Id: hal-01608081

https://hal.archives-ouvertes.fr/hal-01608081

Submitted on 3 Jun 2020

HAL is a multi-disciplinary open access

archive for the deposit and dissemination of sci-entific research documents, whether they are pub-lished or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L’archive ouverte pluridisciplinaire HAL, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d’enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.

Copyright

The MeLiM pig : a model for cutaneous melanoma

Emmanuelle Bourneuf, Josef Janda, Silvia Vincent-Naulleau

To cite this version:

Emmanuelle Bourneuf, Josef Janda, Silvia Vincent-Naulleau. The MeLiM pig : a model for cutaneous melanoma. COST Action BM1308 “Sharing Advances in Large Animal Models” (SALAAM), Dec 2014, Munich, Germany. 2014, Proceedings of the Opening Conference COST Action BM1308 Sharing Advances on Large Animal Models. �hal-01608081�

(2)

P19 The MeLiM pig: a model for cutaneous melanoma

E. Bourneuf1, J. Janda2, S. Vincent-Naulleau1

1Animal Genetics and Integrative Biology Unit, INRA, CEA, DSV/iRCM/SREIT/LREG,

Domaine de Vilvert, 78352 Jouy-en-Josas, France.

2Laboratory of Tumor Biology, Institute of Animal Physiology and Genetics, The Academy of

Sciences of the Czech Republic, Libechov. Czech Republic

Cutaneous melanoma has been a public health concern for several decades, with a growing incidence in Caucasian populations. Tumors arise from skin melanocytes, the pigment-producing cells. The only efficient therapy described so far is an early resection of the primary tumor, as treatment options for invasive melanoma have been limited until recently. Novel molecular and immune therapies are now improving patient outcomes, nevertheless

complementary insights from melanoma biology and immunology research must be pursued.

Like most neoplasms, genetic and environmental factors favor melanoma development. Most tumors are a consequence of UV exposure, which damages skin cells DNA and favors cell transformation. Nevertheless, a significant proportion (10-20%) of patients carries a genetic susceptibility to melanoma. Despite huge efforts of the scientific community to decipher melanoma mechanisms, animal models are still needed to accelerate the discovery of the genetic basis of the disease and investigate potential therapeutic approaches.

The MeLiM pig (melanoblastoma-bearing Libechov Minipig) is a highly relevant model for many aspects of melanoma. Piglets develop tumors spontaneously at birth of within the first two months of life, without any human intervention. Following a tumor progression phase, and eventually a metastatic process, all lesions undergo a spontaneous regression, leading to an absence of malignant cells in adult animals. A histological and clinical comparison of the lesions observed in the MeLiM pig with human tumors has shown similarities between the two species. Obviously, discrepancies exist as well, such as the early-onset of tumors and the spontaneous regression process. However, these phenomena can provide exciting research lines. The model is maintained both in the Institute of Animal Physiology and Genetics of Libechov (Czech Republic), and in the National Institute of Agronomical Research in Jouy-en-Josas (France). Several research programs are developed, aiming at a better understanding of melanoma appearance and regression.

For example, we could evidence, in the MeLiM genome, loci that carry genes and variants predisposing to melanoma. Based on very promising results, a precise cross-species comparison with human and dog genetic data is underway. Concerning oncogenesis, a transcriptomic survey of purified melanocytes and melanoma cells gives insight into early mechanisms of transformation. Molecular investigations performed on the regression phenomenon have shown a precocious cell cycle arrest of tumor cells, in parallel of an efficient immune response, leading to tumor regression and eventually a local or systemic vitiligo-like depigmentation of the animals. Current investigations are based on the precise characterization of the tumor-infiltrating immune cells.

Finally, the MeLiM model has been used to study the effect of therapeutic molecules, and to test innovative imaging methods for example.

Funding: French Research Agency, National League Against Cancer, Cancer Research Association, French National Cancer Institute, INRA, CEA.

Références

Documents relatifs

This topic will be addressed in the context of the GANIP (General Adaptive Neighborhood Image Processing) [2] approach which is a mathematical framework for nonlinear processing

(3) that the contributions due from the former Czechoslovakia in respect of the year 1993 under resolution WHA45.15 shall be replaced by the contributions due from the Czech

Following the dissolution of Czechoslovakia on 31 December 1992, the Czech Republic and the Slovak Republic, both Members of the United Nations, became Members of the World

The NHIS is defined by law as a state-wide information system responsible for collecting and processing information on the health status of the population, on health care

Among households who are further impoverished by spending on health – people living below the basic needs or poverty line and incurring out-of- pocket payments – the average

Availability of regional information on the internet can be researched minimally in two levels: the local information resources and the nationwide information

L’archive ouverte pluridisciplinaire HAL, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des

A series of interviews was conducted with representatives from NICE (including the Directors of each of the guidance programs, the R&D program and the Patient and Public